Business Context and Reporting Period
This Form 8-K is filed by Athira Pharma, Inc. (not Leonabio, Inc.) on October 7, 2024, reporting events occurring on October 1, 2024. The filing details the departure of two senior executives and the implementation of retention incentives for remaining leadership following a previously announced workforce reduction.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation costs.
- Separation Payments: $375,000 to Rachel Lenington (former COO/CDO) and $363,750 to Andrew Gengos (former CBO/CFO), representing nine months of base salary each.
- Consulting Fees: $41,666.67 per month for Rachel Lenington through December 31, 2024.
- Equity Grants: 325,000 RSUs and options to CEO Mark Litton; 37,077 RSUs and options to VP of Finance Robert Renninger.
- Option Exercise Prices: $0.4257 per share for Dr. Litton; $0.4499 per share for Mr. Renninger.
Material Changes
Effective October 1, 2024, the Company terminated the employment of Andrew Gengos and Rachel Lenington. Concurrently, the Company entered into separation agreements providing lump-sum payments and COBRA coverage. Additionally, a consulting agreement was executed with Ms. Lenington to provide services through the end of 2024.
Guidance, Outlook, and Risks
The filing outlines retention incentives approved to stabilize leadership:
- Equity Vesting: New RSUs and stock options for the CEO and VP of Finance vest in three equal tranches on December 31, 2024, June 30, 2025, and December 31, 2025, contingent on continued service.
- Cash Retention: A program to automatically increase the 2024 Corporate Goals achievement percentage by 25 percentage points for eligible executives.
- Risks: The filing notes that the 2024 Corporate Goals achievement percentage has not yet been determined. The agreements include standard confidentiality and non-disparagement covenants.
Investor Verification Checklist
- Verify the total cash outflow for separation payments ($738,750) and the projected consulting fees for Ms. Lenington.
- Confirm the dilution impact of the 362,077 new RSUs and stock options granted to the CEO and CFO.
- Review the full text of Exhibits 10.1 and 10.2 for specific terms regarding the release of claims and non-compete provisions.
- Monitor future filings for the determination of the 2024 Corporate Goals achievement percentage to calculate final cash retention payouts.